Treatment and Prevention of Pre-Chronic Heart Failure Pre-Chronic heart failure is the asymptomatic phase and the longest period in the entire course of heart failure, where health checkups and corresponding prevention are most important. As we said before, stage A is the “pre-heart failure stage”, where there is no change in the structure of the heart, mainly in patients with hypertension, coronary heart disease, diabetes, etc., but also in patients with obesity, metabolic syndrome and other conditions that can eventually involve the heart. The treatment of these patients is also the treatment of heart failure in that stage, which means that patients with hypertension should have their blood pressure strictly controlled, patients with diabetes should have their blood sugar controlled, and patients with coronary artery disease should have their coronary plaques controlled from developing in order to protect their target organ, the heart. Treatment at the source before structural changes to the heart occur is the best means of controlling heart failure, and certainly the one least valued by many patients. With the development of evidence-based medicine, the training of physicians, including primary care physicians, the application of antiplatelet drugs, ACEI, statins, etc., the treatment strategy has been basically formalized; however, in this aspect of patients, it is often not as good as it should be, most notably the concept that the target organs (heart, brain, kidneys) are not in trouble. The most prominent is the perception that the target organs (heart, brain, kidney) are not in trouble, so they do not insist on the treatment of the above diseases, especially there are many misconceptions about antihypertensive and hypoglycemic treatment, coupled with the propaganda of socially beneficial behaviors, so that patients do not know what to do and eventually miss the disease. In terms of examination, chest X-ray, cardiac ultrasound, cardiac exercise stress test and coronary CT should be done regularly to understand the heart structure and assess the coronary artery condition. The heart has undergone structural changes, including myocardial hypertrophy, valvular lesions, myocardial infarction, and chamber enlargement. Myocardial hypertrophy is mainly seen in hypertension, which is caused by increased afterload of the heart. Chest radiography mostly suggests enlarged heart shadow and boot-shaped heart, but cardiac ultrasound will reveal myocardial hypertrophy, and the heart chambers are not enlarged or even reduced; treatment is based on blood pressure control; the causes of valvular lesions are mostly degenerative, with hypertension and old age as the main causes, mostly mitral regurgitation and aortic regurgitation or stenosis, and cardiac ultrasound is most sensitive to valvular Myocardial infarction is the most significant, most aggressive, and by far the most common disease causing structural changes in the heart. Most patients have no structural changes in the heart before myocardial infarction occurs, while continuous changes occur after myocardial infarction, called myocardial remodeling. This structural change in the myocardium is a progressive process with both advantages and disadvantages, as described earlier, and the treatment of this process is critical, requiring the preservation of the surviving myocardium first and then the application of drugs that slow down myocardial remodeling, such as ACEI, ARB, and beta-blockers, under the guidance of a physician. In addition to etiologic treatment and treatment to slow down myocardial remodeling, it is very important to assess the structural and functional status of the heart. The main purpose of such evaluation is to adjust the treatment in time, to delay the myocardial remodeling as much as possible, to prolong the process of asymptomatic myocardial structural changes, especially in the process of heart enlargement, to use ACEI and beta-blockers as much as possible, the former can delay the myocardial remodeling, the latter can reduce the energy consumption of the myocardium, delay the energy consumption of the heart chambers and degenerative changes of the valves, to increase the ” service life”. For patients, in addition to regular checkups and cooperation with therapy, an appropriate exercise regimen is important.